AffiliationCR-UK Department of Medical Oncology, Christie Hospital, Manchester, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractOvarian steroids, acting through nuclear receptors, are crucial players in normal breast development and cancer. Estrogen, in particular, is the focus of breast cancer therapies because tumours are often dependent on this steroid for growth. Recently, novel genes and/or protein isoforms of receptors for both estrogen and progesterone have been discovered, leading us to reappraise their roles in breast development and cancer. Recognition of changes in estrogen receptor biology that occur in the transition from normal development to cancer has emphasized its contribution to tumorigenesis. In addition, complex interactions with other signalling pathways, particularly growth factor pathways, have recently come to the forefront. These interactions might explain resistance to endocrine treatments and offer solutions in terms of novel therapeutic targets.
CitationSteroid receptors in human breast cancer. 2004, 15 (7):316-23 Trends Endocrinol. Metab.
JournalTrends in Endocrinology and Metabolism
- Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
- Authors: Hoffmann J, Sommer A
- Issue date: 2005 Feb
- New approaches to reverse resistance to hormonal therapy in human breast cancer.
- Authors: Weinberg OK, Marquez-Garban DC, Pietras RJ
- Issue date: 2005 Aug
- The biology of breast carcinoma.
- Authors: Keen JC, Davidson NE
- Issue date: 2003 Feb 1
- Membrane-initiated steroid action in breast and prostate cancer.
- Authors: Kampa M, Pelekanou V, Castanas E
- Issue date: 2008 Oct
- Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
- Authors: Kim HJ, Cui X, Hilsenbeck SG, Lee AV
- Issue date: 2006 Feb 1